28 February 2012 in Journal of Ophthalmology
Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.
1 January 2019 in Survey of Ophthalmology
9 February 2021 in Ocular Immunology and Inflammation
To describe eight patients with toxoplasma retinochoroiditis following exposure to wild game.Retrospective, multicenter case seriesEight men, aged 29 to 71 (mean, 56 years), developed toxoplasmic r...
1 April 2016 in Ophthalmology
MPMargaret A. Pericak-Vance
Margaret A. Pericak-Vance
+2
1 November 2010 in Ophthalmic Surgery, Lasers and Imaging Retina
Persistent placoid maculopathy is a rare entity characterized by bilateral well-delineated whitish plaque-like lesions in the macula. Secondary choroidal neovascularization and extensive retinal pigment epithelial damage, highlighted by spectral domain optical coherence tomography and autofluorescence imaging, can limit visual prognosis. Aggressive immunosuppression can preserve vision and perhaps delay the onset of choroidal neovascularization.